Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144418 | PMC |
http://dx.doi.org/10.4103/heartviews.heartviews_124_22 | DOI Listing |
JTCVS Open
February 2025
Division of Cardiovascular Surgery, Department of Surgery, University of Florida Health, Gainesville, Fla.
Background: Transvenous cardiac implantable electronic device (CIED) lead extraction (TLE) is susceptible to superior vena cava (SVC) injury and can be performed in the operating room (OR) or electrophysiology lab via a mechanical device or laser-powered extraction. This study reflects a contemporary experience of mechanical right-left rotational extraction by cardiac surgeons in the OR.
Methods: We conducted a retrospective single-center review of adult (age ≥18 years) TLE cases performed by cardiac surgeons between 2019 and 2021.
World J Cardiol
February 2025
Department of Cardiology, King George's Medical University, Lucknow 226003, Uttar Pradesh, India.
Cardiac resynchronization therapy (CRT) reduces heart failure (HF) hospitalizations and all-cause mortality in patients with HF with reduced ejection fraction with left bundle branch (LBB) block. Biventricular pacing (BVP) is considered the gold standard for achieving CRT; however, approximately 30%-40% of patients do not respond to BVP-CRT. Recent studies have demonstrated that LBB pacing (LBBP) produces remarkable results in CRT.
View Article and Find Full Text PDFCJC Open
February 2025
Barts Heart Centre, St Bartholomew's Hospital, London, UK.
Background: Cardiac resynchronization therapy (CRT) response relies on 2 factors: when and where to pace. These factors may be enhanced by dynamic atrioventricular delays (AVDs) (eg, SyncAV CRT, Abbott Cardiovascular, Abbott Park, IL) and multisite left ventricular (LV) pacing (eg, MultiPoint Pacing [MPP], Abbott). Their individual and combined synchronization contributions have not been evaluated across a comprehensive spectrum of pacing configurations.
View Article and Find Full Text PDFJACC Case Rep
March 2025
Department of Cardiology, Santa Marta Hospital, Unidade Local de Saúde São José, Lisbon, Portugal; Faculty of Medicine of Lisbon, Cardiovascular Centre of the University of Lisbon, Lisbon, Portugal.
Background: Baroreflex activation therapy (BAT) is a novel treatment for heart failure with reduced ejection fraction (HFrEF) in patients who remain symptomatic despite optimal medical therapy (OMT) and who are unsuitable for cardiac resynchronization therapy (CRT). BAT modulates the autonomic nervous system by electrically stimulating carotid baroreceptors, thus potentially improving heart function and symptoms.
Cases Summary: Two male HFrEF patients with nonischemic cardiomyopathy, symptomatic (NYHA functional class III) despite OMT, underwent successful BAT implantation.
Curr Cardiol Rev
March 2025
Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Introduction: Advances in cardiac implanted electronic devices (CIED) have significantly improved outcomes for patients with heart failure. However, there is a bereft of recent real- world data on the relative effectiveness of cardiac resynchronization therapy with pacing and defibrillator (CRT-D) and continuous resynchronization therapy with pacing (CRT-P) in patients with nonischemic cardiomyopathy (NICM). We hypothesized that the addition of defibrillation therapy in patients with NICM would offer no significant benefit.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!